ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Community-acquired Bacterial Pneumonia Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-19C7457
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global Community acquired Bacterial Pneumonia Market Insights Forecast to 2028
BUY CHAPTERS

Global Community-acquired Bacterial Pneumonia Market Research Report 2025

Code: QYRE-Auto-19C7457
Report
July 2025
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer
Lupin Pharmaceuticals
Mylan N.V.
Sanofi
Pfizer Inc
Dainippon sumitomo pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

Community-acquired Bacterial Pneumonia Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Community-acquired Bacterial Pneumonia Market

Community-acquired Bacterial Pneumonia Market

The global market for Community-acquired Bacterial Pneumonia was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Community-acquired Bacterial Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community-acquired Bacterial Pneumonia.
The Community-acquired Bacterial Pneumonia market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Community-acquired Bacterial Pneumonia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Community-acquired Bacterial Pneumonia companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Community-acquired Bacterial Pneumonia Market Report

Report Metric Details
Report Name Community-acquired Bacterial Pneumonia Market
CAGR 5%
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica International AG
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Community-acquired Bacterial Pneumonia company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Community-acquired Bacterial Pneumonia Market report?

Ans: The main players in the Community-acquired Bacterial Pneumonia Market are Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica International AG

What are the Application segmentation covered in the Community-acquired Bacterial Pneumonia Market report?

Ans: The Applications covered in the Community-acquired Bacterial Pneumonia Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Community-acquired Bacterial Pneumonia Market report?

Ans: The Types covered in the Community-acquired Bacterial Pneumonia Market report are Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, Others

Recommended Reports

Pulmonary Disease Drugs

Respiratory Vaccines & Prevention

Diagnostics & Devices

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Pleuromutilin Antibiotic
1.2.3 Cephalosporin
1.2.4 Glycylcycline
1.2.5 Oxazolidinone
1.2.6 Ketolide
1.2.7 Others
1.3 Market by Application
1.3.1 Global Community-acquired Bacterial Pneumonia Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Community-acquired Bacterial Pneumonia Market Perspective (2020-2031)
2.2 Global Community-acquired Bacterial Pneumonia Growth Trends by Region
2.2.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Community-acquired Bacterial Pneumonia Historic Market Size by Region (2020-2025)
2.2.3 Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2026-2031)
2.3 Community-acquired Bacterial Pneumonia Market Dynamics
2.3.1 Community-acquired Bacterial Pneumonia Industry Trends
2.3.2 Community-acquired Bacterial Pneumonia Market Drivers
2.3.3 Community-acquired Bacterial Pneumonia Market Challenges
2.3.4 Community-acquired Bacterial Pneumonia Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue
3.1.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue (2020-2025)
3.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2020-2025)
3.2 Global Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Community-acquired Bacterial Pneumonia Revenue
3.4 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio
3.4.1 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Community-acquired Bacterial Pneumonia Revenue in 2024
3.5 Global Key Players of Community-acquired Bacterial Pneumonia Head office and Area Served
3.6 Global Key Players of Community-acquired Bacterial Pneumonia, Product and Application
3.7 Global Key Players of Community-acquired Bacterial Pneumonia, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Community-acquired Bacterial Pneumonia Breakdown Data by Type
4.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Type (2020-2025)
4.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2026-2031)
5 Community-acquired Bacterial Pneumonia Breakdown Data by Application
5.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Application (2020-2025)
5.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Community-acquired Bacterial Pneumonia Market Size (2020-2031)
6.2 North America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025)
6.4 North America Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Community-acquired Bacterial Pneumonia Market Size (2020-2031)
7.2 Europe Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025)
7.4 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size (2020-2031)
8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2020-2025)
8.4 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Community-acquired Bacterial Pneumonia Market Size (2020-2031)
9.2 Latin America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025)
9.4 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2020-2031)
10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025)
10.4 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nabriva Therapeutics
11.1.1 Nabriva Therapeutics Company Details
11.1.2 Nabriva Therapeutics Business Overview
11.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Introduction
11.1.4 Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.1.5 Nabriva Therapeutics Recent Development
11.2 Paratek Pharmaceuticals
11.2.1 Paratek Pharmaceuticals Company Details
11.2.2 Paratek Pharmaceuticals Business Overview
11.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction
11.2.4 Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.2.5 Paratek Pharmaceuticals Recent Development
11.3 Melinta Therapeutics
11.3.1 Melinta Therapeutics Company Details
11.3.2 Melinta Therapeutics Business Overview
11.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Introduction
11.3.4 Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.3.5 Melinta Therapeutics Recent Development
11.4 Allergan plc
11.4.1 Allergan plc Company Details
11.4.2 Allergan plc Business Overview
11.4.3 Allergan plc Community-acquired Bacterial Pneumonia Introduction
11.4.4 Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.4.5 Allergan plc Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Community-acquired Bacterial Pneumonia Introduction
11.5.4 Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.5.5 Bayer AG Recent Development
11.6 Lupin Pharmaceuticals
11.6.1 Lupin Pharmaceuticals Company Details
11.6.2 Lupin Pharmaceuticals Business Overview
11.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction
11.6.4 Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.6.5 Lupin Pharmaceuticals Recent Development
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Details
11.7.2 Mylan N.V. Business Overview
11.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Introduction
11.7.4 Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.7.5 Mylan N.V. Recent Development
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Details
11.8.2 Sanofi S.A. Business Overview
11.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Introduction
11.8.4 Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.8.5 Sanofi S.A. Recent Development
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Details
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Introduction
11.9.4 Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.9.5 Pfizer Inc. Recent Development
11.10 Dainippon Sumitomo Pharma
11.10.1 Dainippon Sumitomo Pharma Company Details
11.10.2 Dainippon Sumitomo Pharma Business Overview
11.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Introduction
11.10.4 Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.10.5 Dainippon Sumitomo Pharma Recent Development
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Takeda Pharmaceutical Company Limited Company Details
11.11.2 Takeda Pharmaceutical Company Limited Business Overview
11.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Introduction
11.11.4 Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.11.5 Takeda Pharmaceutical Company Limited Recent Development
11.12 Basilea Pharmaceutica International AG
11.12.1 Basilea Pharmaceutica International AG Company Details
11.12.2 Basilea Pharmaceutica International AG Business Overview
11.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Introduction
11.12.4 Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025)
11.12.5 Basilea Pharmaceutica International AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer
Lupin Pharmaceuticals
Mylan N.V.
Sanofi
Pfizer Inc
Dainippon sumitomo pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG
List of Tables
 Table 1. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Pleuromutilin Antibiotic
 Table 3. Key Players of Cephalosporin
 Table 4. Key Players of Glycylcycline
 Table 5. Key Players of Oxazolidinone
 Table 6. Key Players of Ketolide
 Table 7. Key Players of Others
 Table 8. Global Community-acquired Bacterial Pneumonia Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Community-acquired Bacterial Pneumonia Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Community-acquired Bacterial Pneumonia Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Community-acquired Bacterial Pneumonia Market Share by Region (2020-2025)
 Table 12. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Community-acquired Bacterial Pneumonia Market Share by Region (2026-2031)
 Table 14. Community-acquired Bacterial Pneumonia Market Trends
 Table 15. Community-acquired Bacterial Pneumonia Market Drivers
 Table 16. Community-acquired Bacterial Pneumonia Market Challenges
 Table 17. Community-acquired Bacterial Pneumonia Market Restraints
 Table 18. Global Community-acquired Bacterial Pneumonia Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Community-acquired Bacterial Pneumonia Market Share by Players (2020-2025)
 Table 20. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2024)
 Table 21. Ranking of Global Top Community-acquired Bacterial Pneumonia Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Community-acquired Bacterial Pneumonia Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Community-acquired Bacterial Pneumonia, Headquarters and Area Served
 Table 24. Global Key Players of Community-acquired Bacterial Pneumonia, Product and Application
 Table 25. Global Key Players of Community-acquired Bacterial Pneumonia, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Community-acquired Bacterial Pneumonia Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2020-2025)
 Table 29. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2026-2031)
 Table 31. Global Community-acquired Bacterial Pneumonia Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2020-2025)
 Table 33. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2026-2031)
 Table 35. North America Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Nabriva Therapeutics Company Details
 Table 51. Nabriva Therapeutics Business Overview
 Table 52. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product
 Table 53. Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 54. Nabriva Therapeutics Recent Development
 Table 55. Paratek Pharmaceuticals Company Details
 Table 56. Paratek Pharmaceuticals Business Overview
 Table 57. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product
 Table 58. Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 59. Paratek Pharmaceuticals Recent Development
 Table 60. Melinta Therapeutics Company Details
 Table 61. Melinta Therapeutics Business Overview
 Table 62. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product
 Table 63. Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 64. Melinta Therapeutics Recent Development
 Table 65. Allergan plc Company Details
 Table 66. Allergan plc Business Overview
 Table 67. Allergan plc Community-acquired Bacterial Pneumonia Product
 Table 68. Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 69. Allergan plc Recent Development
 Table 70. Bayer AG Company Details
 Table 71. Bayer AG Business Overview
 Table 72. Bayer AG Community-acquired Bacterial Pneumonia Product
 Table 73. Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 74. Bayer AG Recent Development
 Table 75. Lupin Pharmaceuticals Company Details
 Table 76. Lupin Pharmaceuticals Business Overview
 Table 77. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product
 Table 78. Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 79. Lupin Pharmaceuticals Recent Development
 Table 80. Mylan N.V. Company Details
 Table 81. Mylan N.V. Business Overview
 Table 82. Mylan N.V. Community-acquired Bacterial Pneumonia Product
 Table 83. Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 84. Mylan N.V. Recent Development
 Table 85. Sanofi S.A. Company Details
 Table 86. Sanofi S.A. Business Overview
 Table 87. Sanofi S.A. Community-acquired Bacterial Pneumonia Product
 Table 88. Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 89. Sanofi S.A. Recent Development
 Table 90. Pfizer Inc. Company Details
 Table 91. Pfizer Inc. Business Overview
 Table 92. Pfizer Inc. Community-acquired Bacterial Pneumonia Product
 Table 93. Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 94. Pfizer Inc. Recent Development
 Table 95. Dainippon Sumitomo Pharma Company Details
 Table 96. Dainippon Sumitomo Pharma Business Overview
 Table 97. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product
 Table 98. Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 99. Dainippon Sumitomo Pharma Recent Development
 Table 100. Takeda Pharmaceutical Company Limited Company Details
 Table 101. Takeda Pharmaceutical Company Limited Business Overview
 Table 102. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product
 Table 103. Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 104. Takeda Pharmaceutical Company Limited Recent Development
 Table 105. Basilea Pharmaceutica International AG Company Details
 Table 106. Basilea Pharmaceutica International AG Business Overview
 Table 107. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product
 Table 108. Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2020-2025) & (US$ Million)
 Table 109. Basilea Pharmaceutica International AG Recent Development
 Table 110. Research Programs/Design for This Report
 Table 111. Key Data Information from Secondary Sources
 Table 112. Key Data Information from Primary Sources
 Table 113. Authors List of This Report


List of Figures
 Figure 1. Community-acquired Bacterial Pneumonia Picture
 Figure 2. Global Community-acquired Bacterial Pneumonia Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Community-acquired Bacterial Pneumonia Market Share by Type: 2024 VS 2031
 Figure 4. Pleuromutilin Antibiotic Features
 Figure 5. Cephalosporin Features
 Figure 6. Glycylcycline Features
 Figure 7. Oxazolidinone Features
 Figure 8. Ketolide Features
 Figure 9. Others Features
 Figure 10. Global Community-acquired Bacterial Pneumonia Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Community-acquired Bacterial Pneumonia Market Share by Application: 2024 VS 2031
 Figure 12. Hospital Pharmacies Case Studies
 Figure 13. Retail Pharmacies Case Studies
 Figure 14. Online Pharmacies Case Studies
 Figure 15. Community-acquired Bacterial Pneumonia Report Years Considered
 Figure 16. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 17. Global Community-acquired Bacterial Pneumonia Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Community-acquired Bacterial Pneumonia Market Share by Region: 2024 VS 2031
 Figure 19. Global Community-acquired Bacterial Pneumonia Market Share by Players in 2024
 Figure 20. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2024)
 Figure 21. The Top 10 and 5 Players Market Share by Community-acquired Bacterial Pneumonia Revenue in 2024
 Figure 22. North America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. North America Community-acquired Bacterial Pneumonia Market Share by Country (2020-2031)
 Figure 24. United States Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Canada Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2020-2031)
 Figure 28. Germany Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. France Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. U.K. Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Italy Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Russia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Nordic Countries Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2020-2031)
 Figure 36. China Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Japan Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. South Korea Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. India Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Australia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2020-2031)
 Figure 44. Mexico Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Brazil Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2020-2031)
 Figure 48. Turkey Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. UAE Community-acquired Bacterial Pneumonia Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Nabriva Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 52. Paratek Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 53. Melinta Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 54. Allergan plc Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 55. Bayer AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 56. Lupin Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 57. Mylan N.V. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 58. Sanofi S.A. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 59. Pfizer Inc. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 60. Dainippon Sumitomo Pharma Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 61. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 62. Basilea Pharmaceutica International AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2020-2025)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Pneumonia Vaccine Market Insights Forecast to 2030
Ventilator Associated Pneumonia VAP Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Haemophilus Influenzae Infection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pneumococcal Bacteria Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Streptococcus Pneumoniae Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chlamydia Infection Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hospital Acquired Urinary Tract Infection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Streptococcus Pneumoniae Antibodies Market Research Report 2024
Pneumococcal Vaccine Polyvalent Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pneumonia Therapeutics Market Research Report 2024
Global Bacterial Disease Diagnostics Market Insights Forecast to 2030
Global Pneumococcal Testing Market Research Report 2024
Gram Negative lnfections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Multivalent Pneumococcal Conjugate Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bronchiectasis Drugs Market Insights Forecast to 2030
Community Acquired Bacterial Pneumonia CABP Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Klebsiella Pneumoniae Infection Drug Market Research Report 2024
PCR For Respiratory Infection Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hospital Infection Prevention And Control Market Insights Forecast to 2030
Dental Infection Prevention Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Inhaled Treatment for Asthma and COPD Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Y19888
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Oxygen Inhaler Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-11D3386
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26D2937
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Bronchiectasis Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-18E6080
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions